Accendra Health risk analysis
Want to see ACCH full AI Analyst Report?
Accendra Health (ACCH) Risk Analysis
Risk Overview Q3, 2026
Source: the company's latest filing for the period ended Sep 30, 2026, filed Nov 05, 2026
Risk Change Over Time
- Share Price & Shareholder Rights - Risk 1The market price for our common stock does not meet the New York Stock Exchange (NYSE) continued listing requirements and our efforts to cure the noncompliance may be unsuccessful.
Our common stock is subject to continued listing requirements on the NYSE as set forth in the NYSE's Listed Company Manual. As previously disclosed, on October 6, 2026, we received notice from the NYSE that we were not in compliance with its continued listing standards because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period. This notice has no immediate impact on the listing of our common stock on the NYSE, subject to our compliance with the NYSE's other continued listing requirements. We have a period of six months following the receipt of this notice to regain compliance with the minimum share price requirement. We intend to cure the NYSE minimum stock price listing requirement through a reverse stock split, which requires shareholder approval. We have called a special meeting of shareholders to approve a reverse stock split at a ratio in the range of 1-for-20 to 1-for-30. We cannot assure that the reverse stock split proposal will be approved and implemented. As previously disclosed, on October 27, 2026, we received notice from the NYSE that we were not in compliance with its continued listing standards because we have an average market capitalization of less than $50 million over a consecutive 30 trading-day period and stockholders' equity of less than $50 million. This notice has no immediate impact on the listing of our common stock on the NYSE, subject to our compliance with the NYSE's other continued listing requirements. We have a period of 18 months following receipt of this notice to regain compliance with the market capitalization and stockholders' equity requirement. The Company is considering a number of available alternatives to cure its non-compliance with this NYSE continued listing standard. The NYSE will review the Company's business plan and, if accepted, the Company will be subject to quarterly monitoring by the NYSE of the progress of the business plan. While we intend to regain compliance, the NYSE could ultimately delist our common stock if we fail to do so. Given our recent stock price decline and recent financial challenges, including the loss of significant Payor contracts, and the divestiture of our P&HS business, there is a risk that our stock price could remain below the minimum share price requirement. If our stock were delisted and traded on the over-the-counter market, it would significantly reduce liquidity, make it more difficult for shareholders to sell their shares, impair our ability to raise capital and could have a material adverse effect on our business operations and our financial condition, results of operations and cash flows.
Risk Highlights Q3, 2026
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 39
- Share Price & Shareholder Rights - Risk 1AddedThe market price for our common stock does not meet the New York Stock Exchange (NYSE) continued listing requirements and our efforts to cure the noncompliance may be unsuccessful.
Our common stock is subject to continued listing requirements on the NYSE as set forth in the NYSE's Listed Company Manual. As previously disclosed, on October 6, 2026, we received notice from the NYSE that we were not in compliance with its continued listing standards because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period. This notice has no immediate impact on the listing of our common stock on the NYSE, subject to our compliance with the NYSE's other continued listing requirements. We have a period of six months following the receipt of this notice to regain compliance with the minimum share price requirement. We intend to cure the NYSE minimum stock price listing requirement through a reverse stock split, which requires shareholder approval. We have called a special meeting of shareholders to approve a reverse stock split at a ratio in the range of 1-for-20 to 1-for-30. We cannot assure that the reverse stock split proposal will be approved and implemented. As previously disclosed, on October 27, 2026, we received notice from the NYSE that we were not in compliance with its continued listing standards because we have an average market capitalization of less than $50 million over a consecutive 30 trading-day period and stockholders' equity of less than $50 million. This notice has no immediate impact on the listing of our common stock on the NYSE, subject to our compliance with the NYSE's other continued listing requirements. We have a period of 18 months following receipt of this notice to regain compliance with the market capitalization and stockholders' equity requirement. The Company is considering a number of available alternatives to cure its non-compliance with this NYSE continued listing standard. The NYSE will review the Company's business plan and, if accepted, the Company will be subject to quarterly monitoring by the NYSE of the progress of the business plan. While we intend to regain compliance, the NYSE could ultimately delist our common stock if we fail to do so. Given our recent stock price decline and recent financial challenges, including the loss of significant Payor contracts, and the divestiture of our P&HS business, there is a risk that our stock price could remain below the minimum share price requirement. If our stock were delisted and traded on the over-the-counter market, it would significantly reduce liquidity, make it more difficult for shareholders to sell their shares, impair our ability to raise capital and could have a material adverse effect on our business operations and our financial condition, results of operations and cash flows.
- Share Price & Shareholder Rights - Risk 2Our amended and restated bylaws designate the U.S. District Court for the Eastern District of Virginia as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us.
Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the U.S. District Court for the Eastern District of Virginia, (or, if such court lacks subject matter jurisdiction, another state or federal court located within the Commonwealth of Virginia) will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a duty owed to the Company by any director or officer or other employee of the Company or the Company's shareholders, (iii) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the Virginia Stock Corporation Act, our articles of incorporation or our amended and restated bylaws (as applicable) or (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine. In addition, our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the U.S federal district courts shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. The forum selection clause in our amended and restated bylaws may have the effect of discouraging lawsuits against us or our directors and officers and may limit our stockholders' ability to obtain a favorable judicial forum for disputes with us.
- Share Price & Shareholder Rights - Risk 3The market price for our common stock and debt have been, and may continue to be, highly volatile.
A variety of factors may have a significant impact on the market price of our common stock and debt, including, but not limited to: the publication of earnings estimates or other research reports and speculation in the press or investment community; changes in our financial projections or our failure to meet these projections; changes in our industry and competitors; changes in government or legislation; government debt and/or budget crises; changes in our Board or management; our financial condition, results of operations and cash flows and prospects; activism by any single large shareholder or combination of shareholders; lawsuits threatened or filed against us; any future issuances of our common stock, which may include primary offerings for cash, stock splits, issuances in connection with business acquisitions, issuances of restricted stock/units and the grant or exercise of stock options from time to time; the trading volume of our common stock and debt; general market and economic conditions; any future outbreaks, and any future pandemics; the threat or outbreak of war, terrorism or public unrest (including, without limitation, geopolitical conflicts, including the war in Ukraine, conflicts in the Middle East, or tensions involving other regions); and the other factors discussed in this Item 1A. "Risk Factors," any of which could have a material effect on us. The stock and bond markets have recently experienced extreme price and volume fluctuations. The market prices of securities of companies have experienced fluctuations that often have been unrelated or disproportionate to their operating results. In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted against companies. This type of litigation, if instituted, could result in substantial costs and a diversion of management's attention and resources, which could have a material adverse effect on our business. Additionally, our common stock is subject to continued listing requirements on NYSE, including maintaining a minimum $1.00 share closing price for a period of 30 consecutive trading days. If the closing bid price of our common stock falls below $1.00 per share for 30 consecutive trading days, NYSE could issue a deficiency notice and ultimately delist our common stock if we fail to regain compliance. Given our recent stock price and recent financial challenges, including the loss of significant Payor contracts, goodwill impairment charges and the divestiture of our P&HS business, there is a risk that our stock price could fall below the minimum share price requirement. If our stock were delisted and traded on the over-the-counter market, it would significantly reduce liquidity, make it more difficult for shareholders to sell their shares, impair our ability to raise capital and could have a material effect on our business operations and our financial condition, results of operations and cash flows.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.

